Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMGN151 · 2 trials · 8 indications
Dose limiting toxicities (DLTs) of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
| Arm | Type | Description |
|---|---|---|
| Arm A: IMGN151 + Carboplatin (For PSOC) | EXPERIMENTAL | Participants will receive IMGN151 in combination with Carboplatin on Day 1 of a 21-day cycle. |
| Arm B: IMGN151 + Olaparib (For PSOC) | EXPERIMENTAL | Participants will receive IMGN151 in combination with Olaparib twice a day (BID) on Day 1 of a 21-day cycle. |
| Arm C: IMGN151 + Bevacizumab (For PSOC or PROC) | EXPERIMENTAL | Participants will receive IMGN151 in combination with Bevacizumab Day 1 of a 21-day cycle. |
| Arm D: IMGN151 Monotherapy (For PSOC) | EXPERIMENTAL | Participants will receive IMGN151 Day 1 of a 21-day cycle. |
| Arm E: IMGN151 Monotherapy (For PROC in China) | EXPERIMENTAL | Participants will receive IMGN151 Day 1 of a 21-day cycle. |
| Arm F: IMGN151 Monotherapy (For PROC in Japan) | EXPERIMENTAL | Participants will receive IMGN151 Day 1 of a 21-day cycle. |
| IMGN151 | EXPERIMENTAL | IMGN151 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 every 3-week cycle (Q3W). |
| Name | Type | Description |
|---|---|---|
| IMGN151 | DRUG | Intravenous (IV) infusion |
| Carboplatin | DRUG | Intravenous (IV) infusion |
| Bevacizumab | DRUG | Intravenous (IV) infusion |
| Olaparib | DRUG | Oral Tablet |
Inclusion Criteria: * ECOG performance status of 0 or 1 * Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression after platinum combination standard of care therapy in Arms B and D) will have ≥ 1 lesion that...
IMGN151 is an investigational oncology therapy being studied for the treatment of gynecologic cancers, including endometrial cancer, high grade serous adenocarcinoma of the ovary, primary peritoneal carcinoma, fallopian tube cancer, cervical cancer, and platinum-sensitive ovarian cancer. It is currently in clinical development and has not been approved by regulatory authorities.
IMGN151 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is currently in Phase 1 and Phase 2 clinical trials for gynecologic cancers.
IMGN151 is in Phase 1 and Phase 2 clinical development. A Phase 1 study is active but not recruiting, and a Phase 2 study is currently recruiting participants. The drug is investigational and has not received regulatory approval.
IMGN151 is being studied in two clinical trials. NCT05527184 is a Phase 1 first-in-human study in recurrent gynecological cancers, active but not recruiting. NCT07024784 is a Phase 2 study of IMGN151 as monotherapy or in combination for gynecologic cancers, currently recruiting.
No alternative names for IMGN151 have been disclosed. The drug is identified solely by its code name IMGN151 in clinical trial registrations and is being developed by AbbVie Inc.